Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
药物研究
动物造模剂
/
动物造模剂
免疫与炎症疾病模型 消化系统疾病模型
/
胃肠炎症及溃疡模型
胃肠道疾病模型 炎症模型
/ Cysteamine HCl/半胱胺盐酸盐

Cysteamine HCl/半胱胺盐酸盐 {[allProObj[0].p_purity_real_show]}

货号：A542078 同义名： 2-巯基乙基胺盐酸盐 / 2-Aminoethanethiol hydrochloride; 2-Mercaptoethylamine hydrochloride

Cysteamine HCl 是通过辅酶A在哺乳动物中的降解生物合成的，主要用于半胱氨酸尿症的研究。

Cysteamine HCl/半胱胺盐酸盐 化学结构 CAS号：156-57-0
Cysteamine HCl/半胱胺盐酸盐 化学结构
CAS号：156-57-0
Cysteamine HCl/半胱胺盐酸盐 3D分子结构
CAS号：156-57-0
Cysteamine HCl/半胱胺盐酸盐 化学结构 CAS号：156-57-0
Cysteamine HCl/半胱胺盐酸盐 3D分子结构 CAS号：156-57-0
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Cysteamine HCl/半胱胺盐酸盐 纯度/质量文件 产品仅供科研

货号：A542078 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

Cysteamine HCl/半胱胺盐酸盐 生物活性

描述 Cysteamine hydrochloride (2-Aminoethanethiol hydrochloride) is an orally active agent for the treatment of nephropathic cystinosis and an antioxidant[1]. Cysteamine hydrochloride (2-Aminoethanethiol hydrochloride) effectively increases intracellular glutathione levels in cystinotic cells, helping to restore their altered redox state. It demonstrates a dose-dependent impact on the doxorubicin-induced death of cancer cells, with significant effects observed in both HeLa and B16 cells. Notably, while Cysteamine hydrochloride alone does not affect cell survival, its combination with doxorubicin significantly enhances cell death in doxorubicin-resistant breast cancer cell lines, highlighting its potential to improve chemotherapy outcomes[1]. Additionally, at a concentration of 100 μM, Cysteamine hydrochloride markedly boosts intracellular glutathione (GSH) levels and enhances the developmental progression of embryos, significantly increasing the proportion of matured oocytes that reach the blastocyst stage in culture[2].
体外研究

Cysteamine hydrochloride (2-Aminoethanethiol hydrochloride) is an orally active agent for the treatment of nephropathic cystinosis and an antioxidant[1].

Cysteamine hydrochloride (2-Aminoethanethiol hydrochloride) effectively increases intracellular glutathione levels in cystinotic cells, helping to restore their altered redox state. It demonstrates a dose-dependent impact on the doxorubicin-induced death of cancer cells, with significant effects observed in both HeLa and B16 cells. Notably, while Cysteamine hydrochloride alone does not affect cell survival, its combination with doxorubicin significantly enhances cell death in doxorubicin-resistant breast cancer cell lines, highlighting its potential to improve chemotherapy outcomes[1].

Additionally, at a concentration of 100 μM, Cysteamine hydrochloride markedly boosts intracellular glutathione (GSH) levels and enhances the developmental progression of embryos, significantly increasing the proportion of matured oocytes that reach the blastocyst stage in culture[2].

Cysteamine HCl/半胱胺盐酸盐 细胞实验

Cell Line
Concentration Treated Time Description References
Pseudomonas aeruginosa DgcvP2 mutant 200 mg/L 24 hours Cysteamine inhibited glycine utilization by P. aeruginosa DgcvP2 mutant Front Cell Infect Microbiol. 2021 Sep 22;11:718213.
Pseudomonas aeruginosa PAO1 200 mg/L 24 hours Cysteamine inhibited glycine utilization by P. aeruginosa PAO1 Front Cell Infect Microbiol. 2021 Sep 22;11:718213.
Gilthead sea bream (Sparus aurata) myocytes 200 µM 4 days To evaluate cell viability and GH/IGF axis-related gene expression. Results showed that CSH treatment increased cell viability and upregulated mRNA levels of ghr1, igf-1b, igf-2, and igf-1rb compared to the control group. Front Endocrinol (Lausanne). 2023 Jul 20;14:1211470.
Calu-3 cells 500-125 µM 48 hours To assess the impact of cysteamine and cystamine on SARS-CoV-2 replication. Results demonstrated that both compounds significantly reduced viral production. Cells. 2021 Dec 24;11(1):52.
THP-1 cells 800 µM 48 hours Restricted intracellular replication compared to the untreated control Int J Mol Sci. 2023 Jan 7;24(2):1203.
THP-1 cells 400 µM 48 hours Restricted intracellular replication compared to the untreated control Int J Mol Sci. 2023 Jan 7;24(2):1203.
Burkholderia cepacia complex (BCC) clinical isolates and type strains 128 μg/ml 48 hours To assess the utility of cysteamine as an adjunct antibiotic therapy against BCC in vitro, results showed that cysteamine potentiated the activity of tobramycin, ciprofloxacin, and trimethoprim-sulfamethoxazole, reversing resistance in some strains. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6200-6.
Peripheral blood mononuclear cells (PBMCs) 50-400 µM 6 hours and 24 hours To evaluate the immunomodulatory effects of cysteamine on Th1 and Tc1 cell responses. Results showed that cysteamine at 400 µM significantly reduced PPD- and SEB-induced Th1 and Tc1 responses. Front Immunol. 2024 Oct 28;15:1411827.
Vero E6 cells 500-31.25 µM 72 hours To evaluate the effect of cysteamine and cystamine on SARS-CoV-2-induced cytopathic effects (CPE). Results showed that both compounds significantly reduced SARS-CoV-2-induced CPE in a dose-dependent manner. Cells. 2021 Dec 24;11(1):52.

Cysteamine HCl/半胱胺盐酸盐 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Gilthead sea bream (Sparus aurata) Fingerlings (1.8 ± 0.03 g) and juveniles (14.46 ± 0.68 g) Oral 1.65 g/kg or 3.3 g/kg 9 and 18 weeks To investigate the effects of CSH on growth performance and the GH/IGF-1 axis. Results showed that CSH-1.65 improved growth performance by 16% and 26.7% after 9 and 18 weeks, respectively, while CSH-3.3 improved 32.3% after 18 weeks. CSH reduced plasma GH levels after 18 weeks and increased IGF-1 levels after 9 and 18 weeks. Front Endocrinol (Lausanne). 2023 Jul 20;14:1211470.
Gilthead sea bream (Sparus aurata) Fingerlings (1.8 ± 0.03 g) and juveniles (14.46 ± 0.68 g) Oral 1.65 g/kg or 3.3 g/kg of feed 9 and 18 weeks To investigate the effects of CSH on growth performance and the GH/IGF-1 axis. Results showed that CSH-1.65 improved growth performance by 16% and 26.7% after 9 and 18 weeks, respectively, while CSH-3.3 improved 32.3% after 18 weeks. CSH reduced plasma GH levels after 18 weeks and increased IGF-1 levels after 9 and 18 weeks. Front Endocrinol (Lausanne). 2023 Jul 20;14:1211470.
Mice Heterozygous reeler mice (HRM) Through drinking water 150 mg/kg/day 30 days To evaluate the potential of cysteamine to improve the deficits in GAD67 expression and cognitive function in HRM. Results showed that cysteamine significantly ameliorated the decreases in GAD67, mature BDNF and full-length TrkB protein levels in frontal cortex and hippocampus of HRM. Additionally, cysteamine improved Y-maze spatial recognition in HRM to the level of wide-type controls and improved PPI in both wild-type and HRM. Int J Neuropsychopharmacol. 2012 Sep;15(8):1073-86
Galleria mellonella Galleria mellonella larvae infection model Injection 2, 20, 100, 200 mg/L Single injection, observed for 48 hours Cysteamine significantly reduced the toxicity of P. aeruginosa secreted factors Front Cell Infect Microbiol. 2021 Sep 22;11:718213.
LDL receptor-deficient mice High-fat diet-induced atherosclerosis model Drinking water 2.2 mM (equivalent to 42 mg/kg/day) Changed daily for 8 weeks Cysteamine caused regression of atherosclerosis by 32% to 56%, increased markers of plaque stability, reduced liver inflammation and lipid levels, and improved skeletal muscle function. J Am Heart Assoc. 2021 Sep 21;10(18):e017524

Cysteamine HCl/半胱胺盐酸盐 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00074516 - Completed - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00006466 Multiple Myeloma and Plasma Ce... 展开 >>ll Neoplasm Precancerous Condition 收起 << Phase 1 Phase 2 Unknown - United States, Georgia ... 展开 >> Emory Clinic Atlanta, Georgia, United States, 30322 United States, Maryland Victory Over Cancer Rockville, Maryland, United States, 20852 United States, New York St. Vincents Comprehensive Cancer Center New York, New York, United States, 10011 收起 <<
NCT00041379 Lymphoma Phase 1 Phase 2 Unknown - United States, Maryland ... 展开 >> Victory Over Cancer Rockville, Maryland, United States, 20852 收起 <<

Cysteamine HCl/半胱胺盐酸盐 参考文献

[1]Besouw, M., et al., Cysteamine: an old drug with new potential. Drug Discov Today, 2013. 18(15-16): p. 785-92.

[2]de Matos, D.G., et al., Effect of cysteamine on glutathione level and developmental capacity of bovine oocyte matured in vitro. Mol Reprod Dev, 1995. 42(4): p. 432-6.

Cysteamine HCl/半胱胺盐酸盐 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

8.80mL

1.76mL

0.88mL

44.01mL

8.80mL

4.40mL

88.02mL

17.60mL

8.80mL

Cysteamine HCl/半胱胺盐酸盐 技术信息

CAS号156-57-0
分子式C2H8ClNS
分子量 113.61
SMILES Code NCCS.[H]Cl
MDL No. MFCD00012904
别名 2-巯基乙基胺盐酸盐 ;2-Aminoethanethiol hydrochloride; 2-Mercaptoethylamine hydrochloride; β-Mercaptoethylamine; CI-9148; Cysteamine (hydrochloride); Mercaptamine; Cysteamine HCl
运输蓝冰
InChI Key OGMADIBCHLQMIP-UHFFFAOYSA-N
Pubchem ID 9082
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Inert atmosphere, 2-8°C
溶解方案

DMSO: 105 mg/mL(924.22 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(440.1 mM)

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二
方案 三
配制的工作液建议现用现配，短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。
方案 一

Tags: Cysteamine hydrochloride | 2-Aminoethanethiol hydrochloride;2-Mercaptoethylamine hydrochloride;β-Mercaptoethylamine;CI-9148;Cysteamine (hydrochloride);Mercaptamine;Cysteamine HCl | 2-巯基乙基胺盐酸盐 | Inflammation Model | AmBeed-信号通路专用抑制剂 | Cysteamine HCl/半胱胺盐酸盐 纯度/质量文件 | Cysteamine HCl/半胱胺盐酸盐 生物活性 | Cysteamine HCl/半胱胺盐酸盐 临床数据 | Cysteamine HCl/半胱胺盐酸盐 参考文献 | Cysteamine HCl/半胱胺盐酸盐 实验方案 | Cysteamine HCl/半胱胺盐酸盐 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z